Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Cancer Discovery
|
August 30, 2012
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation
Stefan T Börno, Axel Fischer, Martin Kerick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Cancer Discovery
|
February 13, 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Ryan B Corcoran, Thierry André, Chloe E Atreya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2017
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, et al.
Cancer Treatment Reviews
|
January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini, Tomás Pascual, Benedetta Conte, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Cancer Discovery
|
August 30, 2012
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation
Stefan T Börno, Axel Fischer, Martin Kerick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Cancer Discovery
|
February 13, 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Ryan B Corcoran, Thierry André, Chloe E Atreya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2017
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, et al.
Cancer Treatment Reviews
|
January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini, Tomás Pascual, Benedetta Conte, et al.
Page
of 6